Table 1. Baseline characteristics (12‐week double‐blind study) in glimepiride monotherapy (+ placebo), alogliptin 12.5 mg and alogliptin 25 mg groups.
| Placebo + glimepiride n = 103 | Alogliptin 12.5 mg + glimepiride n = 105 | Alogliptin 25 mg + glimepiride n = 104 | |
|---|---|---|---|
| Male/female (n) | 71/32 | 67/44 | 70/43 |
| Age (years) | 60.3 (9.11) | 60.5 (9.50) | 59.8 (9.10) |
| Weight (kg) | 65.19 (12.58) | 65.02 (12.79) | 64.28 (13.73) |
| Height (cm) | 161.7 (8.15) | 161.2 (8.50) | 162.4 (9.16) |
| BMI (kg/m2) | 24.84 (3.90) | 24.89 (3.81) | 24.29 (4.40) |
| Diabetes duration (years) | 9.37 (7.38) | 9.59 (7.03) | 10.38 (6.86) |
| HbA1c (%) | 8.62 (0.78) | 8.54 (0.81) | 8.54 (0.79) |
| Fasting C‐peptide (ng/mL) | 1.77 (0.79) | 1.86 (0.79) | 1.65 (0.93) |
| 2‐h postprandial PG (mg/dL) | 279.2 (62.19) | 276.7 (58.06) | 277.7 (64.13) |
| Glimepiride dose (mg/day), No. (%) patients | |||
| 1 | 37 (35.9) | 36 (34.3) | 37 (35.6) |
| 2 | 31 (30.1) | 34 (32.4) | 32 (30.8) |
| 3 | 13 (12.6) | 13 (12.4) | 13 (12.5) |
| 4 | 22 (21.4) | 22 (21.0) | 22 (21.2) |
Values shown are mean (SD). BMI, body mass index; HbA1c, glycosylated hemoglobin; PG, plasma glucose.